Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Parkinson disease

Can pharmacological activation of 4E-BP suppress PD?

Nature Reviews Neurology volume 5, page 578 (2009)Cite this article

Tain, L. S. et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12, 1129–1135 (2009)

Administration of rapamycin suppresses PD-like phenotypes in Drosophila mutants, Tain and colleagues have shown. The drug upregulates the activity of 4E-BP, a protein that is crucial to cellular survival responses and which genetically interacts with PD-related genes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Overexpression of 4E-BP in the Drosophila brain.
Authors
  1. Eleanor Beal
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beal, E. Can pharmacological activation of 4E-BP suppress PD?. Nat Rev Neurol 5, 578 (2009). https://doi.org/10.1038/nrneurol.2009.171

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.171

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing